The data are incrementally positive but not a stock-moving catalyst — the Phase 3 EMPEROR readout in Q3 2027 is the key binary event. Monitor for any regulatory updates or changes to the NDA timeline. The 4-year durability data de-risks the mechanism modestly but does not change the probability of success for the pivotal study.
Price Chart
Executive Summary
Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen in Dravet syndrome at the European Epilepsy Congress, showing durable seizure reductions and cognitive/behavioral improvements. The Phase 3 EMPEROR study data readout is anticipated in Q3 2027, with a rolling NDA submission planned for H2 2027. This is a clinical update with no financial terms disclosed, and the stock-moving catalyst remains the Phase 3 results over a year away.
Key Facts
- 4-year OLE data showed 93% (75/81) of eligible patients continued treatment; 77% (58/75) remained at data cutoff
- Statistically significant improvements in cognition and behavior at 1, 2, 3, and 4 years vs OLE baseline
- Substantial reductions in generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures through 3 years
- Quality of life improvements demonstrated through 28 months via EQ-VAS
- Phase 3 EMPEROR study (n=162 in primary analysis population) data readout expected Q3 2027
- Rolling NDA submission to FDA planned for H2 2027
- Zorevunersen generally well tolerated; >930 doses administered as of July 31, 2026
- Elevated CSF protein in ~94% of patients, 59% as treatment-emergent AE; no serious clinical manifestations or hydrocephalus
- Stoke retains US/Canada/Mexico rights; Biogen has rest-of-world commercialization rights
Financial Impact
No financial terms or deal values disclosed in this press release. The collaboration structure (Stoke retains North America, Biogen rest-of-world) was previously announced.
Risk Factors
- Phase 3 EMPEROR study may fail to replicate Phase 1/2a results
- Elevated CSF protein, while asymptomatic to date, could become a safety signal in larger/longer trials
- Competing Dravet syndrome therapies (e.g., fenfluramine, stiripentol, cannabidiol) may erode market opportunity
- Regulatory approval timeline could slip beyond H2 2027
- Commercialization depends on partnership execution between Stoke and Biogen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access